StockData

Korsana Biosciences vs Neuphoria Therapeutics

KRSA and NEUP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRSA and NEUP compare

Korsana Biosciences scores higher on the StockData Score (6 against 5 for Neuphoria Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRSANEUP
Size and price
Market cap$152M–
Share price$32.50$2.27
Change, 1 year241%−52.6%
Change, 5 years−90.5%–
Beta (5Y)5.730.82
Employees17
StockData Score
Total score6 (better)5
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score45 (better)
Dividend score00
Valuation
P/S80.1×–
P/B29.9×–
Fair value$5.48–
Margin of safety−493%–
Growth
Revenue growth (TTM)−12.6%–
Revenue growth, 5Y average−2.0%–
Profitability
Operating margin−359%–
Net margin−353%–
Return on equity−98.2%−61.7% (better)
Return on invested capital−116% (better)−273%
Financial health
Debt / equity0.000.00
Current ratio0.8227.85 (better)
Altman Z-score−9.25–
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions15.1%36.8%
Insider net buying, 12 months–$0

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.